Dr. John Cush RheumNow
4 years 4 months ago
Forbes review on how patients can save on the cost of prescription meds https://t.co/zbFMJdOI0W https://t.co/O2RQSrLwZY
Dr. John Cush RheumNow
4 years 4 months ago
Large Korean population study compares pts w/ palmoplantar psoriasis vs psoriasis and PPP pts have more risk for ankylosing spondylitis (aOR 1.37) & Graves dz (aOR 1.4) but lower risk for PsA (aOR 0.54), SLE (0.67); Sjögren (0.70); vitiligo (0.53) https://t.co/zrlvJpOhqc https://t.co/rxrEVHuUgm
JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi). Dermatologists often refer to this side effect as "JAKne".
Dr. John Cush RheumNow
4 years 4 months ago
Insurance delays in starting TNF Inhibitors in kids w/ Juvenile Idiopathic Arthritis (91% on DMARDs) - prior authorization required in 98%; 26% of PA requests denied & required appeals, w/ 22% delays > 2+ wks, 25% took 30+ days to start TNFi https://t.co/1TGmM8qOHR https://t.co/EpbrNSbNBl
Dr. John Cush RheumNow
4 years 4 months ago
An increasing incidence of RA is driven by increasing # of ACPA-negative RA (but not ACPA-positive RA), partly explained by an ageing population (thus making ACPA-negative RA more prevalent in coming years) https://t.co/AzbYyrOfUG
Dr. John Cush RheumNow
4 years 4 months ago
Canadian study of 6012 Pregnancies w/ +COVID-19 PCR test shows Preg pts increased risk of hospitalization (RR 2.65) & ICU adm (RR 5.46) vs gen population and higher risk of preterm birth vs preg women without COVID (RR 1.63) https://t.co/6UAaa0Jf8j https://t.co/aLQbxZArmq
Dr. John Cush RheumNow
4 years 4 months ago
Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis
https://t.co/n1O4g4HpMM https://t.co/ulF1d2gDkG
Dr. John Cush RheumNow
4 years 4 months ago
GALAXI-1 Study - Guselkumab effective in Crohn's Disease. 309 CD pts (1/2 refractory dz) Rx w/ either PBO, or IV GUS 200 mg, 600 mg, or 1200 mg at weeks 0, 4, and 8; At week 12, all 3 doses had signif. clinical and endoscopic improvements vs PBO https://t.co/ZGAS6W1Rak
The British Society of Rheumatology (BSR) has published evidence-based guidelines for idiopathic inflammatory myopathy (IIM) affecting juvenile and adult-onset disease. This rare condition has an estimated prevalence of 5-15 per 100,000 persons.
Dr. John Cush RheumNow
4 years 4 months ago
Phase 2b DBRPCT of Intranodular injections of adalimumab in 140 pts w/ Dupuytrens contracture showed signif reduction nodule size and hardness ((−4·6 vs −2·2; p=0·0002) at 12 months https://t.co/jXMAyeCL5t https://t.co/0PB81M3v5h
Dr. John Cush RheumNow
4 years 4 months ago
FDA update on Paxlovid - for use pts need to have:
- COVID test +
- Mild-mod dz @ risk for severe COVID
- High risk comorbidity
- potential interaction w/ statins, OCPs, HIV meds
- Dose adjust (nirmatrelvir) w/ CKD
- Dose 3 tabs bid x 5d
- Watch LFTs
https://t.co/oSqwlKijXq https://t.co/3Yx1C23QSz
Dr. John Cush RheumNow
4 years 4 months ago
Study of 13 European registries on durability/effect of interleukin-17 (IL-17) inhibition with secukinumab: among 2,017 PsA on secukinumab, retention rates were 86% and 76% at 6 and 12 mos, with 12 mo remission rate of 11% to 16% https://t.co/03sJBSbUy6
Dr. John Cush RheumNow
4 years 4 months ago
Did you miss last night's TNR on RA, improving future therapy?
We've got you covered. Listen to the playback here.
https://t.co/ci6TZOw3VX https://t.co/31gRUaKbQm
Dr. John Cush RheumNow
4 years 4 months ago
Good free patient info handout on LUMBAR SPINAL STENOSIS from JAMA https://t.co/0CkSR2gqaT
Dr. John Cush RheumNow
4 years 4 months ago
Korean Health Insurance claims data looked at risk of Aortic Regurgitation, Atrial Fib in Axial Spondyloarthritis - 3:1 comparison of normals found axSpA (n 8877) at signif higher risk for aortic regurgitation (HR 2.55) & AF (1.20) https://t.co/BXLDymQDKZ https://t.co/YtUbwmKpkG
